FS-1
Phase 3Small molecule
FS-1 is one of 9 small molecule programs targeting Drug-Resistant Tuberculosis. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Drug-Resistant Tuberculosis
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Deltyba
OtsukaPhase 2
FS-1
SScientific Center for Anti-infectious Drugs, Kazakhstan
Phase 3
Lamprene
NovartisPreclinical
Zyvox
PfizerPreclinical
Sirturo
WWim Janssens
Preclinical
Levaquin
WWim Janssens
Preclinical
TB Alliance
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FS-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details